Member Info for micru

Can't stand this 'host'. Constantly interrupts, mumbles.

https://www.msn.com/en-gb/money/other/why-oxford-biotech-needs-more-than-a-shot-in-the-arm-to-survive/ar-AAZo9uW

“The whole situation makes it very difficult to make your share price grow because there aren’t those long-term investors here. You get people coming in with a very short-term view. The Aim market, I’d say, is on its knees as a market for biotech.”

We have to get back to 6p first, which now feels so distant :-(

1-Jul-22 16:35:00 0.10 845 Buy* 0.09 0.10 0.85 O

Big spender going in for 845 shares after hours. Step aside, Elon Musk.

Does anyone know what this might be? Very strange trade.

Just like last year! Oh wait...

>I'll gladly put a Rambler/chicken video out on my YouTube channel as well :)

"Don't be a c[]ck, buy Rambler stock"

Does anyone remember how in their presentation, they had '2021 will be a very different story', and then they changed the slide to be '2022 will be a very different story'. Looks like time to justify those executive salaries and correct the slide again! Haha.

https://www.theregister.com/2022/07/06/sensyne_nhs_deals/

Spotlight on NHS losses. Should bring focus and scrutiny on doing right by the shareholders.

Quote:
An Oxford University Hospital spokesperson refused to say whether it had since sold the shares. In a statement, it said: "We are in regular contact with the new management of Sensyne and they have suggested a review of the current Strategic Research Agreement (SRA) later in the year. We will carefully consider these proposals when we receive them."

Wherever they're going, I hope they get spiked and buy the tip

https://www.urbandictionary.com/define.php?term=salty

He should diversify into salt mining and get your number!

That is an old/existing OTC market ticker - nothing new.

The subdivision of shares document said nothing new - it's just to confirm the split into ordinary and deferred shares.

List of stakeholders possibly old.

Will be interesting to see what the subdivision of shares ends up looking like. Are they intent on going all out, as per the RNS, or will they self-restrain. And what is the ultimate ambition? $1B valuation?

And also with news of Palantir seeking to dip its toes into NHS data, what does it mean for Sensyne going forward?

https://www.ft.com/content/3f6f24f8-9e5c-42c3-8ae6-bfef5f953524

Thanks for all your posts as well - I wasn't aware I could follow the goings on via Companies House as well - interesting stuff. Any movement and development is interesting, IMO.

It doesn't look like there's anything we didn't already know, the links on the page point to Formal Sales Process Commencement Document dated Nov 2021:
https://assets.website-files.com/5cf7cc8a7a78cd65f38ad273/618eb0e2017707c5b4ad5519_Project%20Redsierra%20-%20Rule%202.11%20Letter%20-%20Shareholders.pdf

This was actually archived back in January 24, 2022, so you can see what was there using the Wayback Machine/Internet Archive website.

Hoping the URL pastes correctly:
https://web.archive.org/web/20220124204427/https://www.sensynehealth.com/investors/offer-related-documents

It's pretty cool to see Auctus springing into action.

They can now use their notes and research to engage potential investors.

Haha, looks like someone had a limit buy for 2.25M shares at 0.01 - brave!

Hey all, hope you are all well.

New vacancy posted:
https://apply.workable.com/sensynehealth/j/C09DD28F4D/

Things are ticking along. Had a look at LinkedIn out of curiosity, hardly any 'opentowork' profiles among current employees.

> Please excuse my ignorance micru. Is there a requirement to be physically present to publish the Final Results?

Don't know, but that aside, just kind of makes sense since their HQ is still in London, is it not? And there's probably a fair bit of work that goes into finalising the results. Not dismissing your point about Auctus, just saying my interpretation of his visit was more routine.